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Abstract
Background: Skeletal characteristics such as height (Ht), bone mineral density (BMD) or bone turnover
markers are strongly inherited. Common variants in the genes encoding for estrogen receptor alpha
(ESR1) and beta (ESR2) are proposed as candidates for influencing bone phenotypes at the population level.
Methods: We studied 641 healthy premenopausal women aged 20–50 years (yrs) participating into the
BONTURNO study. Exclusion criteria were irregular cyclic menses, low trauma fracture, metabolic bone
or chronic diseases. Serum C-telopeptide of type I collagen (CTX), osteocalcin (OC), and N-terminal
propeptide of type I procollagen (P1NP) were measured in all enrolled subjects, who underwent to lumbar
spine (LS), total hip (TH) and femoral neck (FN) BMD evaluation by DXA. Five hundred seventy Caucasian
women were genotyped for ESR1 rs2234693 and rs9340799 and ESR2 rs4986938 polymorphisms.
Results: Although no genotype differences were found in body parameters, subjects with combined ESR1
CCGG plus ESR2 AA-AG genotype were taller than those with opposite genotype (P = 0.044). Moreover,
ESR1 rs2234693 genotypes correlated with family history of osteoporosis (FHO) and hip fracture (FHF)
(P < 0.01), while ESR2 AA-AC genotypes were strongly associated with FHF (OR 2.387, 95% CI 1.432–
3.977; P < 0.001).
When clustered by age, 20–30 yrs old subjects, having at least one ESR1 rs2234693 C allele presented
lower LS- (P = 0.008) and TH-BMD (P = 0.047) than TT genotypes. In 41–50 yrs age, lower FN-BMD was
associated with ESR2 AA (P = 0.0180) subjects than in those with the opposite genotype. ESR1 rs2234693
and rs9340799 and ESR2 rs4986938 polymorphisms did not correlate with age-adjusted values of OC,
CTX and P1NP.
Conclusion: These findings support the presence of age-specific effects of ESR1 and ESR2 polymorphisms
on various skeletal traits in healthy fertile women.
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Bone mass increases during the growth period and peaks
by young adulthood. Although the greatest gain in bone
mass takes place during the accelerated growth in adoles-
cence, bone mineral density (BMD) continues to increase
for several years (yrs) later [1].
The importance of peak bone mass as a determinant of
osteoporosis and fractures later in life is supported by sev-
eral studies. For instance, Hui et al. [2] estimated that peak
bone mass and postmenopausal bone loss contributed
equally to bone status in 70-year-old women. Hernandez
et al. [3] estimated that a 10% increase in peak BMD may
delay the development of osteoporosis by 13 yrs.
Low BMD is, indeed, a major determinant of osteoporotic
fractures, even though environmental factors, such as die-
tary intake and physical activity play an important role in
the BMD determination. From studies of monozygotic
and dizygotic twins, inheritance was estimated to account
for 60–80% of BMD in both men [4] and women [5].
Many other predictors of fragility fracture, bone turnover
markers and skeletal geometry are also under genetic con-
trol. In the last two decades, an exceptionally wide range
of candidate genes have been proposed as risk markers of
osteoporosis outcomes [6], but our ability to predict
which patients are most likely to sustain low BMD and/or
osteoporotic fractures based on genetic screening is still
far to be complete.
Among the analyzed candidate genes are those encoding
estrogen receptor α (ESR1) and β (ESR2). In particular,
single nucleotide polymorphisms [7] defined by the
restriction enzymes PvuII (rs2234693, C/T) and XbaI
(rs9340799, A/G) in the ESR1 intron 1, and by AluI
(rs4986938, A/G) in the 3'-untraslated region (3'UTR) of
ESR2 exon 8 have been evaluated in more than 90 popu-
lation-based studies, with inconclusive results. For their
specific ethnic distribution, clinical predictability of estro-
gen receptor polymorphisms are strongly dependent on
the analysis of homogenous populations [8].
The purpose of this study was to relate skeletal traits such
as height (Ht), BMD and bone turnover markers, meas-
ured in a large cohort of healthy premenopausal Cauca-
sian women aged 20–50 yrs, to several genotyped
polymorphisms in the ESR1 (rs2234693 and rs9340799)
and ESR2 (rs4986938) loci.
Methods
Subject population
The analyzed population included all enrolled partici-
pants in the Bone Turnover Range of Normality (BON-
TURNO) study, a multicenter, multiracial/multiethnic
cohort study from young adulthood to midlife. The
design of the BONTURNO has been described in detail
[9]. A total of 641 subjects were enrolled from 20 different
centers uniformly distributed across Italy. Each center was
asked to recruit four to six healthy individuals for each age
range: 20–24, 25–29, 30–34, 34–39, 40–44, and 45–49.
A prerequisite for the screening was the presence of regu-
lar monthly cyclic menses (cycles occurring every 25–35
days). Subjects were excluded if they had previously suf-
fered a low trauma fracture (as judged by the investigator),
any metabolic bone diseases, or chronic diseases capable
to influence bone metabolism (malignancies, rheumatoid
arthritis, diabetes, etc.). Subjects were also excluded if
abnormal laboratory results in serum calcium, creatinine,
phosphate, and magnesium were found upon screening.
The study sites received formal approval from the local
Ethics Committees and obtained signed informed consent
from each subject before enrolment.
Clinical examination
The subjects considered to be eligible for inclusion in the
study were asked to come to the outpatient clinic by 7:30–
8:30 a.m. in fasting condition for the collection of a blood
sample. Six aliquots of serum samples were separated and
kept on dry ice during transportation by courier to Inter-
lab (Munich, Germany), where they were kept at -80°C
for the later measurements of bone turnover markers in all
subjects, and of follicle stimulating hormone (FSH) and
serum estradiol in women aged >39 yrs. It was preplanned
that women with FSH levels >30 IU/L, despite menstruat-
ing normally, would be analyzed separately and defined
as "perimenopausal".
After breakfast, organized locally, a Dual X-ray (DXA)
evaluation was carried out and a multi-item questionnaire
administrated. Hologic (20 centers) and Lunar (3 centers)
instruments were used for DXA evaluation of BMD at the
lumbar spine (LS), femoral neck (FN) and total hip (TH).
The values obtained with Lunar instruments were stand-
ardized to Hologic instruments [10]. The questionnaire
included personal data and evaluated factors that poten-
tially influence bone turnover, including general health
and any type of continuous use of drugs (including oral
contraceptives or calcium supplements), fracture history,
family (i.e. first degree relative) history of low-energy frac-
tures and/or of osteoporosis (defined by LS- and/or FN-
BMD<-2.0 SDS), number of pregnancies, smoking, alco-
hol consumption, sunlight exposure and menstrual cycle
day. In all subjects body Ht and weight were assessed
(Harpender stadiometer) and the body mass index (BMI,
kg/m2) was derived.
The bone turnover markers investigated in this study were
serum C-telopeptide of type I collagen (CTX), osteocalcin
(OC), and N-terminal propeptide of type I procollagenPage 2 of 8
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diol were measured by automated immunoassay with the
ECLIA device from Roche Diagnostics (Palo Alto, CA,
USA). The coefficients of variation (interassay) provided
by Interlab ranged from 7 to 14%. Additional biochemical
tests performed by local laboratories included serum cal-
cium, creatinine, phosphate, and magnesium.
Genotyping
Genomic DNA was extracted from peripheral blood lym-
phocytes using a column microvolume system (NucleoS-
pin Blood Quick Pure, Macherey-Nagel, Easton, PA, USA)
according to the manufacturer's instructions. Genomic
DNA regions of ESR1 and ESR2 genes, containing the
above described polymorphisms were analyzed by
polymerase chain reactions (PCR), using specific couples
of primers designed by Primer3 (v.0.4.0) program, freely
available [11].
ESR1 gene polymorpisms
Intron 1 region containing both the rs2234693 and
rs9340799 polymorphisms has been amplified by PCR in
a final volume of 50 μl containing 1× of reaction buffer,
0.4 μM of each primer, 0.2 mM of dNTPs, 1 U of GoTaq®
DNA Polymerase (Promega, Madison, WI – USA) and
about 50 ng of genomic DNA. Thermal cycling conditions
were 94°C for 5 min, 35 cycles of 94°C for 30 sec, 60°C
for 30 sec and 72°C for 1 min, followed by an additional
72°C for 5 min stabilization step. Two aliquots of PCR
products were separately digested overnight at 37°C with
1 U of PvuII or XbaI (MBI Fermentas, Vilnius, Lithuania).
PvuII digestion products were visualised by 3% ethidium
bromide stained agarose gel electrophoresis. Fragments
were separated depending on their length revealing pres-
ence or absence of the restriction site and identifying
respectively the T and the C alleles. Similarly, XbaI diges-
tion products were visualised by 3% ethidium bromide
stained agarose gel electrophoresis. Fragments were sepa-
rated depending on their length revealing presence or
absence of the restriction site and identifying respectively
the A and the G alleles.
ESR2 gene polymorphism
PCR amplification was performed in a final volume of 50
μl containing 1× of reaction buffer, 0.4 μM of each primer,
0.2 mM of dNTPs, 1 U of GoTaq® DNA Polymerase
(Promega, Madison, WI – USA) and about 50 ng of
genomic DNA. Thermal cycling conditions were 94°C for
5 min, 35 cycles of 94°C for 30 sec, 60°C for 30 sec and
72°C for 30 sec, followed by an additional 72°C for 5 min
stabilization step. The 168 bp PCR product was digested
over-night at 37°C with 1 U of AluI endonuclease (MBI
Fermentas, Vilnius, Lithuania). AluI digestion products
were visualised by 3% ethidium bromide stained agarose
gel electrophoresis. Fragments were separated depending
on their length revealing presence or absence of the
restriction site and identifying respectively the A and the
G alleles.
Statistical analyses
Data were expressed as mean ± standard deviation (SD)
unless otherwise stated. Statistical evaluation was per-
formed using standard Chi-squared (χ2) test, one-way
analysis of variance (ANOVA) and Pearson's correlation
(r) where multiple samples were obtained. When two sets
of data were compared, an unpaired Student's t-test was
employed. A two-tailed significance test was used for all
comparisons. Standard χ2 test was also used to compare
observed genotype frequencies with those expected under
the Hardy-Weinberg (HW) equilibrium [12]. P < 0.05 was
considered statistically significant. All analyses were per-
formed using the SAS statistical package, version 8.2 (SAS
Institute, Cary, NC).
Results
A total of 641 healthy premenopausal women meeting
the inclusion and exclusion criteria were recruited from 20
investigative sites. Two women were excluded due to
serum calcium >10.5 mg/dL and one patient for P1NP
and OC levels three times above the upper normal range,
who is now under investigation for suspected Paget dis-
ease of the bone. No other patients had abnormal values
of serum phosphate, magnesium or creatinine (data not
shown).
Serum FSH >30 IU/L was found in 18 women even
though menstruating normally. They are considered per
protocol as perimenopausal. Twelve subjects were on
treatment with stable doses of thyroxine, 11 on antihyper-
thensive agents not associated with diuretics, 3 on serot-
onin-uptake inhibitors, and 2 on proton pump inhibitors.
Eighty-three women were on oral contraceptive treatment
[9].
Genetic data were available for 573 enrolled subjects.
Three non-Caucasian women were excluded from genetic
analyses and their exclusion did not modify the results of
the study (data not shown). Statistical analysis was per-
formed on the remaining 570 Caucasian women who
were not on treatment with known bone-active drugs.
The general characteristics of the study population on the
basis of allelic variability for ESR1 and ESR2 loci are
described in Table 1. According to [12], genotype distribu-
tions of these two loci were found to be in HW equilib-
rium (data not shown), suggesting that the enrolled
subjects represented a homogeneous genetic background.
No difference was evidenced in ESR1 and ESR2 loci for all
considered variables, though a tendency to on increased
Ht and a delayed menarche age were detected for ESR1Page 3 of 8
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otypes than for the opposites (P > 0.05, data not shown).
Moreover, the combination of ESR1 CCGG plus ESR2 AA-
AG genotype was significantly taller (164.2 ± 6.06 cm)
than ESR1 TTAA plus ESR2 GG genotype (161.7 ± 6.74
cm; P = 0.044). When ESR1 and ESR2 genotypes were
evaluated alone or in combination, no significant correla-
tion was observed with weight, BMI, heart rate and blood
pressure (P > 0.05).
Regarding family history of osteoporosis (FHO) and of
hip fracture (FHF), no significative association was found
with single or combined analysis of ESR1 polymor-
phisms. In subjects positive both for FHO and for FHF,
the 3 ESR1 rs2234693 genotypes (but not the rs9340799)
were differently distributed than in subjects with double
negative FHO-FHF (χ2 = 10.957, P < 0.01; Table 2), with
odds ratio (OR) of founding ESR1 CT-TT genotypes in
double positive FHO-FHF being 1.836 (95% CI 0.860–
3.919, P = 0.06). No significant association was detected
combining both ESR1 polymorphisms (P > 0.05). Fur-
thermore, ESR2 rs4986938 genotypes correlated with FHF
(χ2 = 11.881, P < 0.01) but not with FHO (P > 0.05), as
having at least one ESR2 rs4986938 A allele correlated
both with positive FHF (χ2 = 11.550, P < 0.001; OR 2.387,
95% CI 1.432–3.977) and with double positive FHO-FHF
(χ2 = 9.407, P < 0.005; OR 2.871, 95% CI 8.804–35.403)
(Table 2). No association was detected co-analyzing ESR1
and ESR2 genotypes (P > 0.05).
The 570 enrolled women were divided in 3 age groups:
from 20 to 30 yrs (class 1), from 31 to 40 yrs (class 2) and
from 41 to 50 yrs (class 3) (Table 3). In class 1, subjects
having at least one ESR1 rs2234693 C allele (i.e. CC and
CT genotypes) presented lower LS-BMD (1.023 ± 0.112 g/
cm2) and TH-BMD (0.927 ± 0.122 g/cm2) than TT geno-
types, respectively (LS-BMD 1.077 ± 0.131 g/cm2, P =
0.0083; TH-BMD 0.969 ± 0.121 g/cm2, P = 0.0474). Sim-
ilar but not significant trends were detected in classes 2
and 3. In class 3, TH-BMD (0.860 ± 0.111 g/cm2) and FN-
BMD (0.738 ± 0.108 g/cm2) of ESR2 rs4986938 AA geno-
type were lower than the opposite GG ones (TH-BMD
0.923 ± 0.130 g/cm2, P = 0.0227; FN-BMD 0.798 ± 0.119
g/cm2, P = 0.0180). Regarding LS-, TH- or FN-BMD, no
other signifivative differences were observed co-analyzing
ESR1 and ESR2 loci.
According to previously published data, oral contracep-
tive users and 18 women considered in perimenopausal
phase for serum FSH levels >30 IU/mL were excluded
from statistic analysis for bone turnover markers [9]. Age
class-adjusted levels of serum OC, CTX and P1NP did not
segregate with ESR1 and ESR2 loci (P > 0.05). Further-
more, no differences between ESR1 and ESR2 polymor-
phisms, were detected for serum age class-adjusted levels
of calcium, phosphate and magnesium (P > 0.05).
Discussion
Low BMD is a major risk factor for spine and proximal
femur fractures [13,14]. In women, BMD in adulthood is
largely determined by the amount of bone accumulated at
the end of their skeletal growth (peak bone mass), their
rate of bone loss after menopause when ovaries cease pro-
Table 1: Genotype variability for ESR1 and ESR2 loci in the 570 
Caucasian women enrolled in the BONTURNO study.
Locus Women (n = 570)
ESR1 rs2234693
CC (n [%]) 123 (21.6)
CT (n [%]) 287 (50.3)
TT (n [%]) 160 (28.1)
ESR1 rs9340799
AA (n [%]) 203 (35.6)
AG (n [%]) 272 (47.7)
GG (n [%]) 95 (16.7)
ESR2 rs4986938
AA (n [%]) 92 (16.2)
AG (n [%]) 266 (46.7)
GG (n [%]) 212 (16.7)
Table 2: Family history of osteoporosis (FHO) and of hip fracture (FHF) regarding ESR1 and ESR2 genotypes.
FHO FHF FHO-FHF FHO FHF FHO-FHF
positive negative
ESR1 rs2234693
CC (n [%]) 39 (17.6) 18 (17.6) 9 (14.7) 77 (24.0) 98 (22.1) 68 (24.1)
CT (n [%]) 118 (53.1) 50 (49.1) 32 (52.5) 158 (49.0) 227 (51.2) 141 (50.0)
TT (n [%]) 65 (29.3) 34 (33.3) 20 (32.8) 87 (27.0) 118 (26.7) 73 (25.9)
Total 222 102 61 322 443 282
ESR2 rs4986938
AA (n [%]) 36 (16.3) 18 (18.2) 12 (19.7) 50 (15.8) 68 (15.5) 44 (15.8)
AG (n [%]) 104 (47.1) 59 (59.6) 38 (62.3) 119 (37.5) 193 (44.0) 127 (45.5)
GG (n [%]) 81 (36.6) 22 (22.2) 11 (18.0) 148 (46.7) 178 (40.5) 108 (38.7)
Total 221 99 61 317 439 279Page 4 of 8
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well established with the study of twins, that peak bone
mass is highly heritable with an estimated heritability
between 0.50 and 0.80 [15]. Conversely, published data
on the heritability of bone loss at menopause are conflict-
ing [16-18]. Therefore, BMD is a trait that lends itself to
studies designed to identify the genes underlying its nor-
mal variation [16,17,19].
The past decade has seen an important increase in the use
of association studies with candidate genes for the genetic
analysis of complex traits such as BMD and/or fracture
risk. Many genes have been examined for their association
with normal BMD variation, which yields an ever-expand-
ing candidate gene list. However, this approach has been
largely criticized because of discrepancy in the results
[20,21], often related to the small size of the enrolled
cohorts. Moreover, most of the studies focused on post-
menopausal female populations. In this view, the main
purpose of the present study was to evaluate allelic influ-
ence of target genes, such as estrogen receptors, on inher-
ited skeletal traits in a large and homogeneous
population-based cohort of premenopausal healthy Cau-
casian women [9].
For ESR1 and ESR2, two genes worldwide evaluated by
independent research groups, the results obtained even if
compelling for their involvement in BMD, osteoporosis,
or fracture, are, however, not conclusive [22]. Confound-
ing factors encompassed ethnic-specific distribution of
ESR1 and ESR2 polymorphisms [8,23,24]. For example,
in the SWAN study [23] which enrolled 693 Caucasian
participants (366 premenopausal women), specific asso-
ciations of BMD with ESR1 and ESR2 genotypes varied
according to race/ethnicity. Furthermore, 4 independent
studies [24] concluded that ESR2 locus could be involved
in FN-BMD in Caucasians, LS-BMD in Japanese postmen-
opausal women, and LS- and FN-BMD in Chinese pre-
menopausal women. In addition, most of the human
studies of genetic association with BMD have been cross-
sectional, and only very few studies examined the associ-
ation of the genotypes to BMD change within specific age
ranges. For all these reasons the present study was aiming
to compare the results obtained for ESR1 and ESR2 to
other data obtained in age-equivalent studies in Cauca-
sian women, examining the relation of ESR1 and ESR2
genes' polymorphisms.
Differently than for the ESR2 locus [25], allelic variants of
ESR1 gene were proposed to affect skeletal growth,
through a genotype-dependent estrogen sensitivity at the
growth cartilage, with the ESR1 px haplotype being less
sensitive to estrogen effects [26]. The ESR1 haplotype
effect was supported by functional studies [27,28] and by
multiple association analysis documented for this gene
variant [29-33]. For example, body Ht in pre- and post-
menopausal women [29] and estradiol levels in premen-
opausal women were lower [30], with the number of
copies of ESR1 px haplotype in their genotype. Lorentzon
et al. [31] found an association between reduced Ht and
PvuII T and XbaI A alleles, which corresponded to the
ESR1 px haplotype. Although this study was performed in
adolescent boys [31], it is in line with other findings in
adult women. In 607 Caucasian women (aged 55–80 yrs)
in whom vertebral fractures were excluded, Schuit et al.
[29] observed significant association between Ht and
ESR1 PvuII-XbaI haplotypes. In contrast to [32], a signifi-
cant allele dose effect was observed for ESR1 px haplotype,
corresponding to a 0.9-cm decrease in Ht per allele copy
(P for trend = 0.02), extreme genotypes varied 1.8 cm.
Table 3: Mean age-class adjusted values (SD) of LS-, TH- and FN-BMD regarding ESR1 and ESR2 genotypes.
Age classes 1 2 3
Subjects (n) 158 192 219
Age range (yrs) 20–30 31–40 41–50
BMD (g/cm2) LS TH FN LS TH FN LS TH FN
ESR1 rs2234693
CC 1.063
(0.134)
0.941
(0.117)
0.859
(0.150)
1.075
(0.138)
0.906
(0.098)
0.821
(0.125)
1.021
(0.122)
0.902
(0.115)
0.778
(0.122)
CT 1.025
(0.112)
0.930
(0.120)
0.845
(0.116)
1.067
(0.122)
0.906
(0.117)
0.795
(0.118)
1.041
(0.127)
0.905
(0.127)
0.789
(0.115)
TT 1.077
(0.131)
0.969
(0.121)
0.874
(0.129)
1.059
(0.106)
0.928
(0.105)
0.813
(0.118)
1.049
(0.125)
0.904
(0.124)
0.777
(0.122)
ESR2 rs4986938
AA 1.039
(0.130)
0.932
(0.110)
0.846
(0.112)
1.059
(0.123)
0.922
(0.110)
0.814
(0.122)
1.044 (0.147) 0.860 (0.111) 0.738
(0.108)
AG 1.044
(0.126)
0.935
(0.125)
0.847
(0.131)
1.076
(0.117)
0.910
(0.106)
0.804
(0.110)
1.032 (0.128) 0.900 (0.118) 0.784
(0.118)
GG 1.056
(0.121)
0.963
(0.122)
0.870
(0.135)
1.056
(0.125)
0.911
(0.115)
0.806
(0.132)
1.046 (0.115) 0.923 (0.130) 0.798
(0.119)Page 5 of 8
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to some extent, as in girls heterozygous for ESR1 px hap-
lotype the Ht was higher than in those homozygous for
the ESR1 px haplotype. In our series, higher Ht was
slightly (P > 0.05) correlated with ESR1 CC, GG or CCGG,
and ESR2 AA genotypes, while ESR1 CCGG plus ESR2 AA-
AG genotype was significantly (2.5-cm) taller than the
opposite genotype. As ESR2 modulates ESR1 transcrip-
tional activity [34], this novel biological interaction
between ESR2 and ESR1 genotypes is not surprising.
Family history is a major risk factor for osteoporotic frac-
tures [35]. In white postmenopausal women, increased
BMD-independent risk for vertebral (but not non-verte-
bral) fractures was found in ESR1 px haplotype carriers
[26]. Moreover, the GENOMOS Consortium found a
BMD-independent protective effect against vertebral frac-
tures in ESR1 XX homozygous individuals, while no
effects on fracture risk were seen for ESR1 PvuII polymor-
phism [22]. Similarly to the InCHIANTI study [36], we
could not demonstrate any strong association between
FHF and ESR1 rs2234693 and rs9340799 genotypes. How-
ever, our study might have had not enough power to
detect any differences.
Variants of ESR2 gene, alone and in interaction with ESR1
genotypes influenced the fracture risk in postmenopausal
women. Moron et al. [37] suggested that ESR2 rs4986938
(but not ESR1 rs2234693) could have a role (P = 0.04) in
osteoporosis in Spanish postmenopausal women. Fur-
thermore, they detected a joint effect of ESR1 gene in oste-
oporosis modulating the penetrance of ESR2 rs4986938
genotype [37]. Rivadeneira et al. [38] showed for the first
time that white postmenopausal women (≥ 55 yrs of age)
who are homozygous for a common intron 2–3'UTR
ESR2 haplotype allele have 40–80% increased risk of fra-
gility and vertebral fracture. Interestingly, we also
observed ESR2 rs4986938 genotypes significantly corre-
lated with FHF risk but not with FHO, suggesting ESR2
variants may affect bone strength independently of BMD.
According to our findings, McGuigan et al. [39] observed
a modest association between ESR1 PvuII genotypes and
BMD at the hip (P = 0.034) but not at the spine in 216
young Irish women (mean age 22.6 ± 1.6 yrs), with no dif-
ferences regarding the ESR1 XbaI locus [39]. On the other
hand, Valero et al. [40] found no significant relations
between FN- or LS-BMD with both ESR1 PvuII and XbaI
loci in 194 older Caucasian women aged 22–45 yrs. Fur-
thermore, a cross sectional study of XbaI and BMD in
women who were premenopausal and perimenopausal,
did not confirm this association [41]. Finally, in perimen-
opausal Caucasian women (older than 48.5 yrs) enrolled
in the GENOMOS consortium, none of two ESR1 intron
1 polymorphisms (i.e. PvuII and XbaI loci) or derived hap-
lotypes had any statistically significant effect on BMD,
with estimated differences between genetic contrasts
being 0.01 g/cm2 or less [22]. Collectively, our findings
and the published studies [22,39-41] make possible to
support a significant effects of the ESR1 rs2234693 (but
not rs9340799) locus on the BMD mainly in the young
adult next to her achievement of bone peak mass.
Previous approaches have also suggested the role of ESR2
in BMD within different ethnic backgrounds [24]. No
association between ESR2 rs4986938 with LS- or FN-BMD
were detected in 1291 Caucasian women (from 192 fam-
ilies) aged 33.2 ± 7.1 yrs (range 20–50 yrs) [42]. Similarly,
no associations between ESR2 rs4986938 genotypes and
Ht, LS-BMD and serum OC levels were detected in 147
healthy peri and postmenopausal Greek women (mean
age 54 ± 7.9 yrs) [25]. On the other hand, we detected sig-
nificant BMD variations of the ESR2 rs4986938 genotypes
only in the later age group (i.e. 41–50 yrs old women).
Together with ESR1 rs2234693 data, this reinforces the
hypothesis that ESR1 and ESR2 genes affect bone metab-
olism in precise and distinct age-sequential windows.
Larger pre-planned analysis will be necessary to confirm
our interpretation.
In conclusion, taken together, our findings indicated that,
although the effect size may be small, allelic variations in
ESR1 and ESR2 genes are associated with various and dif-
ferent bone traits (e.g. Ht, BMD and FHF risk) in normal
premenopausal Caucasian subject. Furthermore, multiple
genotype interactions were detected that reinforced the
polygenic and complex character of skeletal system. In
some cases however, the mean pattern of bone trait values
for a gene polymorphism with evidence of association
was not in agreement with previously published studies.
Therefore, even though family history of fragility fractures
is one of the risk factors [35], we cannot recommend
genetic testing for clinical use in humans to better identify
population at risk for pathologic bone traits such as fragil-
ity fractures. However, as it has been shown for other dis-
eases [43], extended panels of several polymorphic
markers could be used in the future, in addition to tradi-
tional risk factors, to evaluate the skeletal disorder risk in
humans.
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